GlassScriptPhysician profile
James Gerard Ryan
NPI 1659318699
$5,173.74
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,542 · 2020: $1,241 · 2021: $1,295 · 2022: $1,072 · 2023: $23.70.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $23.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $23.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $885.94 | 2019-2022 | |
| Amarin Pharma, INC. | $686.33 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $578.46 | 2019-2022 | |
| Amgen INC. | $482.78 | 2019-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $482.58 | 2019-2023 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $367.31 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $343.57 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $209.55 | 2019-2022 | |
| Pfizer INC. | $160.53 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $122.73 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $115.06 | 2021-2022 | |
| Astellas Pharma US INC | $104.56 | 2019 | |
| Abbott Laboratories | $98.08 | 2019-2022 | |
| Boston Scientific Corporation | $93.00 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $78.47 | 2020-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $64.20 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $63.52 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $52.86 | 2019 | |
| Kiniksa Pharmaceuticals, LTD. | $47.08 | 2022 | |
| Preventice Services, LLC | $40.82 | 2020-2021 | |
| Hikma Pharmaceuticals USA | $33.01 | 2019 | |
| Lantheus Medical Imaging, INC. | $22.45 | 2021 | |
| Philips North America LLC | $13.95 | 2022 | |
| Regeneron Pharmaceuticals, INC. | $13.45 | 2019 | |
| Esperion Therapeutics, INC. | $13.45 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Ryan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.